Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Department of Nuclear Medicine, The Second People's Hospital of Shenzhen, Shenzhen, China.
Cancer Lett. 2018 Sep 1;431:230-243. doi: 10.1016/j.canlet.2017.10.016. Epub 2017 Oct 27.
Nasopharyngeal carcinoma (NPC), which originates from the nasopharynx, is highly prevalent in Southern China and Southeast Asia, and more than 90% of all NPCs are non-keratinizing undifferentiated cells or poorly differentiated squamous cells. Cancer stem cells (CSCs) are capable of self-renewal and have differentiation potential. These properties form the basis of cancer initiation, development, and radiochemoresistance. However, the molecular mechanisms underlying NPC CSC maintenance remain poorly understood. Here, genomic expression profiling using our previously established monoclonal cellular and animal models revealed that interferon regulatory factor 6 (IRF6) was downregulated in highly metastatic NPC cells, cancer stem-like NPC cells and animal models. Functional assays revealed that elevated IRF6 expression suppressed cell proliferation, growth, CSCs properties and enhanced cell chemotherapeutic sensitivity. However, silencing IRF6 resulted in opposing effects. Moreover, we determined that as a tumor suppressor gene and transcription factor, IRF6 directly bound the upstream region of the ATP-binding cassette sub-family G member 2 (ABCG2) DNA element and suppressed target ABCG2 expression in NPC cells. Consistently, an inverse correlation was observed between the mRNA levels of IRF6 and ABCG2 in clinical NPC samples. With these results, we provide the first evidence that IRF6 directly targets the ABCG2 gene and selectively kills CSCs in NPC and that IRF6 may be a valuable tool for developing new CSC-targeted treatment strategies for undifferentiated NPC patients.
鼻咽癌(NPC)起源于鼻咽部,在中国南方和东南亚地区高发,超过 90%的 NPC 为非角化未分化细胞或低分化鳞状细胞。癌症干细胞(CSCs)具有自我更新和分化潜能。这些特性是癌症起始、发展和放化疗耐药的基础。然而,NPC CSC 维持的分子机制仍知之甚少。在这里,使用我们之前建立的单克隆细胞和动物模型进行基因组表达谱分析显示,干扰素调节因子 6(IRF6)在高转移性 NPC 细胞、癌症干细胞样 NPC 细胞和动物模型中下调。功能分析显示,IRF6 的上调抑制了细胞增殖、生长、CSC 特性,并增强了细胞化疗敏感性。然而,IRF6 的沉默则产生了相反的效果。此外,我们确定作为肿瘤抑制基因和转录因子,IRF6 直接结合 ABC 盒亚家族 G 成员 2(ABCG2)DNA 元件的上游区域,并抑制 NPC 细胞中 ABCG2 的表达。在临床 NPC 样本中,IRF6 和 ABCG2 的 mRNA 水平呈负相关。有了这些结果,我们首次提供了证据表明,IRF6 直接靶向 ABCG2 基因,并选择性地杀死 NPC 中的 CSCs,IRF6 可能是为未分化 NPC 患者开发新的 CSC 靶向治疗策略的有价值工具。